ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,281Medicare Part D Prescriptions Filled, Including Refills

Rank: 169 out of 2456

$524K Total Retail Price of All Prescriptions

Rank: 207 out of 2456

491 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 491 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

8% of this provider’s 491 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

3% of this provider’s 8,538 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
SIMVASTATIN 693 600 1 2
OMEPRAZOLE 426 347 2 3
LISINOPRIL 369 300 3 1
HYDROCHLOROTHIAZIDE 345 307 4 7
METFORMIN HCL 333 294 5 11
FUROSEMIDE 270 228 6 8
LEVOTHYROXINE SODIUM 242 175 7 4
METOPROLOL TARTRATE 232 195 8 10
HYDROCODONE-ACETAMINOPHEN 229 175 S3 9 20
AMLODIPINE BESYLATE 227 174 10 5
PRAVASTATIN SODIUM 221 177 11 15
ATORVASTATIN CALCIUM 207 186 12 12
ZOLPIDEM TARTRATE 192 150 13 28
SERTRALINE HCL 178 145 14 21
WARFARIN SODIUM 177 127 15 9
ALLOPURINOL 170 163 16 27
ATENOLOL 156 155 17 6
GLYBURIDE 155 135 R 18 40
LOSARTAN POTASSIUM 138 137 19 18
METOPROLOL SUCCINATE 112 107 20 13
CLOPIDOGREL 106 93 21 55
JANUVIA 101 88 22 81
PROAIR HFA 96 45 23 22
PANTOPRAZOLE SODIUM 93 81 24 37
LISINOPRIL-HYDROCHLOROTHIAZIDE 89 79 25 41
DILTIAZEM 24HR ER 89 65 25 78
PHENYTOIN SODIUM EXTENDED 84 63 27 140
CARVEDILOL 77 74 28 54
LORAZEPAM 70 62 29 67
OXYCODONE-ACETAMINOPHEN 70 46 S2 29 35
ACTOS 69 65 31 124
KLOR-CON M20 67 66 32 69
PLAVIX 66 61 33 79
PAROXETINE HCL 66 66 33 56
CITALOPRAM HBR 65 61 35 14
RANITIDINE HCL 62 11 36 31
NABUMETONE 62 57 36 164
TRIAMCINOLONE ACETONIDE 60 33 38 131
MECLIZINE HCL 55 52 39 107
ZETIA 54 54 40 86
VERAPAMIL ER 53 53 41 91
METHYLPREDNISOLONE 52 49 42 229
GABAPENTIN 50 46 43 16
EVISTA 50 42 43 143
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 2, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.